Cited by 64GDF15 and Related BiomarkersCardiac Fibrosis and RemodelingHeart Failure Treatment and Management

The clinical impact of growth differentiation factor-15 in heart disease: A 2019 update

Arkoumani, Maria, Papadopoulou-Marketou, Nektaria, Nicolaides, Nicolas C., Kanaka-Gantenbein, Christina, Tentolouris, Nikolaos, Papassotiriou, Ioannis·2020·Critical Reviews in Clinical Laboratory Sciences

Abstract

Growth differentiation factor-15 (GDF-15), also known as macrophage inhibitory cytokine-1 (MIC-1) or non-steroidal anti-inflammatory drug-activated gene (NAG-1) has been identified as a biomarker of response to treatment and prognosis in cardiovascular diseases. GDF-15 is a member of the transforming growth factor-β superfamily and is involved in several pathological conditions such as inflammation, cancer, cardiovascular, pulmonary and renal diseases. Cardiac myocytes produce and secrete GDF-15 in response to oxidative stress, stimulation with angiotensin II or proinflammatory cytokines, ischemia, and mechanical stretch. Other cellular sources of GDF-15 production are macrophages, vascular smooth muscle cells, endothelial cells, and adipocytes, which secrete GDF-15 in response to oxidative or metabolic stress or stimulation of proinflammatory cytokines. GDF-15 is induced in hypertrophic and dilated cardiomyopathy after volume overload, ischemia, and heart failure. GDF-15 can be used as a marker of prognosis in patients with cardiovascular disorders, in combination with conventional prognostic factors, such as N-terminal pro B-type natriuretic peptide (NT-proBNP) and high-sensitivity troponin T (hs-TnT).

Integrity signals

Registry

Crossref · 10.1080/10408363.2019.1678565

Cites

79 of 79 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Elevated circulating GDF-15 levels are associated with more severe disease or higher mortality in people with DM2, insulin resistance, hemodialysis, cachexia, cardiovascular diseases, COPD, VTE, cancer, or obesity.

    “Elevated circulating GDF-15 levels have been associated with more severe disease or higher mortality in people with DM2, insulin resistance, hemodialysis, cachexia, cardiovascular diseases, chronic obstructive pulmonary disease (COPD), venous thromboembolism (VTE), cancer, or obesity (28–34).”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Arkoumani, M., Papadopoulou-Marketou, N., Nicolaides, N. C., Kanaka-Gantenbein, C., Tentolouris, N., & Papassotiriou, I.
Affiliations
  • National and Kapodistrian University of Athens (GR)
  • Department of Clinical Biochemistry, “Aghia Sophia” Children's Hospital, Athens, Greece
  • First Department of Pediatrics, Medical School, National and Kapodistrian University of Athens, “Aghia Sophia” Children’s Hospital, Athens, Greece
  • First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, “Laiko” General Hospital, Athens, Greece
  • Children's Hospital Agia Sophia (GR)
Corresponding author
Papassotiriou, Ioannis
Venue
Critical Reviews in Clinical Laboratory Sciences
Published
2019-10-30
Volume
57
Issue
2
Pages
114-125
ISSN
  • 1040-8363 (ISSN-L)
  • 1549-781X
OpenAlex
W2982693936
Cited by
64
References
79
Citations by year
2026: 12 · 2025: 5 · 2024: 12 · 2023: 6 · 2022: 10 · 2021: 7 · 2020: 12
FWCI
1.17
Type
journal article
Language
en
Open access
closed
Locations
  • Critical Reviews in Clinical Laboratory Sciences (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Rheumatology › GDF15 and Related Biomarkers
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords
growth differentiation factor 15, MIC-1, NAG-1, cardiovascular biomarkers, prognosis, heart failure, hypertrophic cardiomyopathy, dilated cardiomyopathy, TGF-beta superfamily, oxidative stress, inflammation, NT-proBNP, high-sensitivity troponin T
MeSH terms
Cardiovascular Diseases, Heart Diseases, Heart Failure, Humans, Inflammation, Predictive Value of Tests, Prognosis, Risk Factors, Biomarkers, Cytokines, Oxidative Stress, Myocytes, Cardiac, Growth Differentiation Factor 15

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review